VANDA PHARMACEUTICALS INC. Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31)
VANDA PHARMACEUTICALS INC. (VNDA) reported Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) of $0 for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-08.
Discontinued › Expense Statement
us-gaap:IncomeTaxExpenseBenefitContinuingOperations · last filed 2013-02-26
- VANDA PHARMACEUTICALS INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for the quarter ending 2012-09-30 was -$50.00K.
- VANDA PHARMACEUTICALS INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for the quarter ending 2011-12-31 was -$600.00K.
- VANDA PHARMACEUTICALS INC. income tax expense (benefit), continuing operations (deprecated 2013-01-31) for fiscal 2011 was -$400.00K.
| Period end | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 3 month | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 6 month | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 9 month | Income Tax Expense (Benefit), Continuing Operations (Deprecated 2013-01-31) 12 month |
|---|---|---|---|---|
| 2012-09-30 | -$50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $0.00 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | $50.00K 10-Q · filed 2012-08-03 | |||
| 2011-12-31 | -$600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$400.00K 10-K · filed 2013-02-26 | ||
| 2011-09-30 | $200.00K 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |